Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan

• Misato Ogata,

  Roles Data curation, Writing – original draft, Writing – review & editing

  Affiliation Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe City, Hyogo, Japan

  http://orcid.org/0000-0003-0793-4247

  ⨯
• Masahito Kotaka,

  Roles Data curation

  Affiliation Gastrointestinal Cancer Center, Sano Hospital, Kobe City, Hyogo, Japan

  http://orcid.org/0000-0001-5976-613X

  ⨯
• Takatsugu Ogata,

  Roles Data curation

  Affiliation Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe City, Hyogo, Japan

  ⨯
• Yukimasa Hatachi,

  Roles Data curation

  Affiliation Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe City, Hyogo, Japan

  ⨯
• Hisateru Yasui,

  Roles Data curation

  Affiliation Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe City, Hyogo, Japan

  ⨯
• Takeshi Kato,

  Roles Conceptualization, Supervision

  Affiliation Department of Surgery, Osaka National Hospital, Osaka City, Osaka, Japan

  ⨯
• Akihito Tsuji,

  Roles Conceptualization, Supervision

  Affiliation Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kitagun, Kagawa, Japan

  ⨯
• Hironaga Satake

  Roles Supervision, Writing – review & editing

  * E-mail: takeh1977@gmail.com

  Affiliations Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe City, Hyogo, Japan, Cancer Treatment Center, Kansai Medical University Hospital, Hirakata City, Osaka, Japan

  ⨯